Advertisement

Topics

FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials

07:38 EDT 31 Aug 2017 | eCliniqua

RAPS |  Today, FDA released an alert and summary findings from two halted Merck clinical trials evaluating the use of Keytruda (pembrolizumab) combined with other treatments in patients with multiple myeloma.


 
 
 
 

Original Article: FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials

NEXT ARTICLE

More From BioPortfolio on "FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...